{"DataElement":{"publicId":"7330047","version":"1","preferredName":"Patient Personal Medical History Malignant Neoplasm Initial Treatment Clinical Trial Eligibility Criteria Confirmation Status","preferredDefinition":"A response to confirm that the patient meets the eligibility requirements to allow clinical trial participation for a personal medical history of cancer, that was initially treated, as outlined in the protocol.","longName":"PMH_CA_INLTX_ELIG","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"7329886","version":"1","preferredName":"Patient Personal Medical History Malignant Neoplasm First Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._Preceding all others in time or space or degree._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:7329884v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7329884","version":"1","preferredName":"Personal Medical History Malignant Neoplasm First Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:Preceding all others in time or space or degree.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"7329884v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BBFAB4-8E7F-5B80-E053-4EBD850AC54D","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BBFAB4-8E90-5B80-E053-4EBD850AC54D","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"TAYLORT","dateModified":"2021-01-11","changeDescription":"EAQ191/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5676955","version":"2","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified._A condition or state at a particular time.","longName":"CONFSTAT","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"11","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unconfirmed","valueDescription":"Negation Confirmation","ValueMeaning":{"publicId":"5676956","version":"1","preferredName":"Negation Confirmation","longName":"5676956","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49380D88-AB51-745A-E053-F662850AA135","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE40-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"Confirmed","valueDescription":"Confirmation","ValueMeaning":{"publicId":"3953314","version":"1","preferredName":"Confirmation","longName":"3953314","preferredDefinition":"Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A874-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-11-18","modifiedBy":"TSESU","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE4A-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE54-165A-E053-4EBD850AA952","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7329879","version":"1","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified.:A condition or state at a particular time.","longName":"C25458:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE19-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE2A-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/10/20 tmt versioned to 2.0 for changes to Long and Short names.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient must have histologica","type":"Preferred Question Text","description":"Patient must have histologically or cytologically-proven advanced metastatic renal cell cancer (mRCC) or medullary thyroid cancer initially treated with anti-angiogenic tyrosine kinase inhibitors (AA-TKIs) including: sunitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, vandetanib, or axitinib).","url":null,"context":"ECOG-ACRIN"},{"name":"EA - 1","type":"Alternate Question Text","description":"Patient must have histologically or cytologically-proven advanced metastatic renal cell cancer (mRCC) or medullary thyroid cancer initiating treatment with anti-angiogenic tyrosine kinase inhibitors (AA-TKIs) including: sunitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, vandetanib, or axitinib).","url":null,"context":"ECOG-ACRIN"},{"name":"EA - 2","type":"Alternate Question Text","description":"Patient must have histologically or cytologically-proven renal cell cancer (mRCC) or thyroid cancer initiating treatment with anti-angiogenic tyrosine kinase inhibitors (AA-TKIs) including: sunitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, vandetanib, or axitinib).","url":null,"context":"ECOG-ACRIN"},{"name":"ECOG ACRIN Text 3","type":"Alternate Question Text","description":"Patient must have renal cell cancer (mRCC) or thyroid cancer initiating treatment with anti-angiogenic tyrosine kinase inhibitors (AA-TKIs) including: sunitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, vandetanib, or axitinib).","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BD8B50-DD1B-3061-E053-4EBD850AB8AD","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"GDEEN","dateModified":"2022-08-01","changeDescription":"EAQ191/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}